Department of Neurobiology & Behavior, University of California Irvine, Irvine, CA 92697, USA; Sue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA 92697, USA; Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, CA 92697, USA.
Department of Neurobiology & Behavior, University of California Irvine, Irvine, CA 92697, USA; Sue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA 92697, USA; Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, CA 92697, USA.
J Mol Biol. 2019 Apr 19;431(9):1805-1817. doi: 10.1016/j.jmb.2019.01.045. Epub 2019 Feb 7.
Research into the function of microglia has dramatically accelerated during the last few years, largely due to recent genetic findings implicating microglia in virtually every neurodegenerative disorder. In Alzheimer's disease (AD), a majority of risk loci discovered through genome-wide association studies were found in or near genes expressed most highly in microglia leading to the hypothesis that microglia play a much larger role in disease progression than previously thought. From this body of work produced in the last several years, we find that almost every function of microglia has been proposed to influence the progression of AD from altered phagocytosis and synaptic pruning to cytokine secretion and changes in trophic support. By studying key Alzheimer's risk genes such as TREM2, CD33, ABCA7, and MS4A6A, we will be able to distinguish true disease-modulatory pathways from the full range of microglial-related functions. To successfully carry out these experiments, more advanced microglial models are needed. Microglia are quite sensitive to their local environment, suggesting the need to more fully recapitulate an in vivo environment to study this highly plastic cell type. Likely only by combining the above approaches will the field fully elucidate the molecular pathways that regulate microglia and influence neurodegeneration, in turn uncovering potential new targets for future therapeutic development.
在过去的几年中,对小胶质细胞功能的研究有了显著的进展,这主要归因于最近的遗传发现表明小胶质细胞几乎与每种神经退行性疾病都有关。在阿尔茨海默病(AD)中,通过全基因组关联研究发现的大多数风险位点都位于或靠近在小胶质细胞中表达水平最高的基因内或附近,这导致了小胶质细胞在疾病进展中发挥的作用比以前认为的要大得多的假设。从过去几年中产生的这一系列研究中,我们发现小胶质细胞的几乎每一种功能都被认为会影响 AD 的进展,从吞噬作用和突触修剪的改变到细胞因子的分泌和营养支持的变化。通过研究 TREM2、CD33、ABCA7 和 MS4A6A 等关键的阿尔茨海默病风险基因,我们将能够区分真正的疾病调节途径和小胶质细胞相关功能的全部范围。为了成功进行这些实验,需要更先进的小胶质细胞模型。小胶质细胞对其局部环境非常敏感,这表明需要更充分地再现体内环境来研究这种高度可塑的细胞类型。可能只有结合上述方法,该领域才能充分阐明调节小胶质细胞和影响神经退行性变的分子途径,从而揭示未来治疗开发的潜在新靶点。